Compared efficacy of rituximab, abatacept, and tocilizumab in patients with rheumatoid arthritis refractory to methotrexate or TNF inhibitors agents: a systematic review and network meta-analysis

CONCLUSION: We found high heterogeneity among studies comparing rituximab, abatacept, and tocilizumab. On multivariate metaregressions, if the conditions of the RCTs were similar, we estimate that abatacept could increase the chance of reaching an ACR70 response by 2.2-fold compared to tocilizumab.PMID:37415193 | DOI:10.1186/s42358-023-00298-z

Source: Adv Data - July 6, 2023 Category: Epidemiology Authors: Alisson Pugliesi Amanda Borges de Oliveira Ana Beatrice Oliveira Ricardo Xavier Licia Maria Henrique da Mota Manoel Barros Bertolo Miguel Angel Gonzalez-Gay Gustavo Citera Luiz Sergio Fernandes de Carvalho Source Type: research